Objective:Panitumumabadministeredasmonotherapyincolorectalcancer(CRC)hasshownresponseanddiseasestabilizationratesofapproximately30%.Thecurrentstudyaimedtoevaluatetheprogression-freesurvival(PFS)andoverallsurvival(OS)ofpatientswithmetastaticcolorectalcancer(mCRC)treatedwithpanitumumabevery3weeksasasecondlinetreatment.Methods:Thisstudyisaretrospectiveanalysisof18patients,agedmorethan18years,withwild-typeKRASexon2mCRCtreatedwithpanitumumabasasecond-linesingleagentafterprogressiononfirst-linechemotherapy.Results:Themediannumberofcoursesreceivedwas10(range,4-29),andthemediandurationoftreatmentwas30weeks(range,12-96weeks).Afteramedianfollow-upperiodof13months,themedianPFSwas6months(range,4.3-7.7months)andthemedianOSwas11months(range,7.4-14.5months).ThemedianPFSwas4monthsforpatientswith